NCT00153569Unknown2 期
Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- Clinical efficacy
研究概览
简要总结
This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic melanoma
- •HLA-A1, -A2, -A24, -B44
排除标准
- 未提供
结局指标
主要结局
Clinical efficacy
次要结局
- Immune response
- Safety
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety Study of Multiple Peptide Vaccine to Esophageal CancerEsophageal CancerNCT00561275Japanese Foundation for Cancer Research6
终止
1 期
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous MelanomaMalignant MelanomaNCT00145158Ludwig Institute for Cancer Research23
已完成
1 期
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of DiseaseBreast CancerNCT00674791Duke University13
Unknown
2 期
Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)Esophageal CancerNCT01267578University of Yamanashi60
Unknown
2 期
A Study With Peptide Vaccination in Treating Patients With Esophageal CancerEsophageal CancerNCT00995358University of Yamanashi60